PSP Research’s Agios Pharmaceuticals AGIO Stock Holding History

PSP Research’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$507K	–	76
2026 Q1	$507K	Buy	+15,000	New	+$425K	0.36%	15

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

PSP Research's AGIO Position: Q2 2026 in Review

PSP Research sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 15,000 shares — an estimated $507K sold.

PSP Research first reported a position in AGIO in Q1 2026 and held it in 1 quarter. The position peaked at $507K in Q1 2026. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

PSP Research reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PSP Research sold 15,000 Agios Pharmaceuticals shares in Q2 2026, an estimated $507K.
PSP Research first reported a position in Agios Pharmaceuticals in Q1 2026 and held it in 1 quarter.
PSP Research's Agios Pharmaceuticals position peaked at $507K in Q1 2026.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.